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COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B
AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS
PATIENTS
Meletiche DM1, Kozma C2, Dickson M3
1EMD Serono, Inc, Rockland, MA, USA, 2University of South Carolina, West Columbia, SC, 
USA, 3University of South Carolina, Columbia, SC, USA
OBJECTIVES: To compare medication adherence to interferon beta (IFNB)-1b and
IFNB-1a subcutaneous (SC) in patients with multiple sclerosis (MS). METHODS: This
was a retrospective analysis of patients with a diagnosis of MS in a national managed 
care database that had q1 outpatient DMD claim during the 7/1/2002 to 12/31/2005 
selection period. Eligible patients were continuously enrolled for 6 months before and 
24 months after their initial drug claim (index date) and were between 18 and 65 
years of age. Medication possession ratios (MPRs) were calculated as the percentage 
of ambulatory days during the 24-month post-index period from the date of ﬁ rst use 
of the index DMD. The primary analysis was logistic regression predicting likelihood 
of adherence (MPR q85%) by treatment group (IFNB-1b versus IFNB-1a SC), includ-
ing covariates of age, sex, and region of the country. RESULTS: A total of 530 MS 
patients (IFNB-1b, n  206, IFNB-1a SC, n  324) met the study criteria. Patients had 
a mean age of 43.6 years, 77.2% were women, 49.0% were located in the Midwest, 
and 94.2% had commercial insurance. Average 2-year MPRs were 57.9% and 63.7% 
(P  0.020) for IFNB-1b and IFNB-1a SC, respectively. The percentage of patients who 
were adherent (MPR q85%) was 39.3% for IFNB-1b vs 49.4% for IFNB-1a SC. A
logistic regression using categorical MPR as the dependent variable found that IFNB-
1a SC patients were signiﬁ cantly more likely to be adherent than IFNB-1b patients 
(OR  1.603, P  0.0110). Older age (in 10 year increments) was also a signiﬁ cant 
predictor of adherence (OR  1.301, P  0.0037). Sex and region of the country were 
not statistically signiﬁ cant. CONCLUSIONS: In this retrospective analysis, patients 
using IFNB-1a SC were more likely to be adherent with their DMD therapy over a 2-
year period than patients using IFNB-1b, while controlling for age, sex, and region of 
the country.
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PREVALENCE OF TREATMENT GAPS IN MULTIPLE SCLEROSIS 
PATIENTS RECEIVING DISEASE-MODIFYING DRUGS: FINDINGS FROM 
A NATIONAL MANAGED CARE DATABASE
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OBJECTIVES: Although gaps in therapy with disease-modifying drugs (DMDs) may 
result in suboptimal treatment for patients with multiple sclerosis (MS), maintaining 
continuous therapy is a challenge in MS care. This study evaluated gaps in DMD
therapy in MS patients. METHODS: In this retrospective study, patients with a diag-
nosis of MS and q1 claim for a self-injectable DMD (index claim) between July 1, 
2000–December 31, 2005 were identiﬁ ed using a national managed care database.
Eligible patients (aged 18 to 65 years) were continuously enrolled for 6 months before
and 24 months after the index date, and had no nursing home claims. The analysis
excluded patients receiving natalizumab because most of the natalizumab claims did 
not contain the necessary days supply data. Maximum gap (MaxGap), which captures 
the maximum period of a given lapse in treatment per patient, was deﬁ ned as the
number of days between the lapsing of days supply of the prior prescription and fulﬁ ll-
ment of a new prescription over the 24-month observation period. MaxGap was also 
assessed between the ﬁ rst and last claim during the observation period. RESULTS: A 
total of 3101 MS patients (76.5% women) met the inclusion criteria for the study. 
The mean o standard deviation patient age was 44.0 o 9.4 years, and most (51.0%)
were from the Midwest. The results showed MaxGaps of q0 and 11 days in 20.5%
of patients, q11 and 31 days in 24.5%, q31 and 61 days in 11.3%, q61 and 
90 days in 6%, and q90 days in 37.7%. When examining the maximum gap between
the ﬁ rst and last prescription claim, 36% of patients had a MaxGap of q31 days.
CONCLUSIONS: Maintaining continuous DMD therapy remains a challenge for MS
patients. Over 24 months, more than one third of patients had a gap in therapy of 
q90 days.
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BURDEN OF MULTIPLE SCLEROSIS ON HEALTH-RELATED QUALITY OF
LIFE: BASELINE FINDINGS FROM AN OBSERVATIONAL STUDY
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OBJECTIVES: To measure health-related quality of life (HRQoL) by SF-12 in multiple 
sclerosis (MS) patients and to compare the SF-12 component scores in MS patients
with available US national average scores (norm). METHODS: ROBUST is an 
ongoing multi-center prospective US observational study among MS patients, involv-
ing a series of questionnaires completed via a web tool. A battery of items in the
patient questionnaire is the SF-12 (Version 2). The ROBUST baseline SF-12 Physical 
Component Summary (PCS-12) and Mental Component Summary (MCS-12) scores 
were analyzed against US population norms. RESULTS: A total of 191 ROBUST
participants completed baseline HRQoL assessments and were included in this analy-
sis. The mean (SD) age was 40.6 (11.2) years and a majority were female (81.2%), 
white (86.9%), married (68.6%) and worked full- or part-time (61.2%). The MCS-12 
showed a gradual increase with the level of education. Among the ROBUST popula-
tion, the mean (SD) scores on PCS-12 [40.64 (11.18)] and MCS-12 [42.54 (11.44)] 
were signiﬁ cantly lower than the norm [PCS-12 norm: 49.63 (p  0.0001); MCS-12 
norm: 49.37 (p  0.0001)]. The PCS-12 [40.11 (11.17)] and MCS-12 [42.42 (11.44)]
scores for female MS patients and the PCS-12 [42.92 (11.08)] and MCS-12 [43.05
(11.55)] scores for male MS patients were also signiﬁ cantly lower than the respective
norms [all p  0.0001]. Similarly, SF-12 scores for MS patients by age groups [18–24 
years; 25–34 years; 35–44 years; 45–54 years; 55–64 years] were signiﬁ cantly lower
compared to norms for corresponding age groups [all p  0.001]. Among these age 
groups within the ROBUST population: PCS-12 scores were lower after 40 years 
compared to that in younger age group, while MCS-12 scores do not show this same 
change with age. CONCLUSIONS: SF-12 component scores were signiﬁ cantly reduced
in the ROBUST population compared to the available national average scores, sug-
gesting a lowering of general HRQoL in MS population.
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THE IMPACT OF LENNOX-GASTAUT SYNDROME (LGS) ON HEALTH
RELATED QUALITY OF LIFE – A CONCEPTUAL MODEL
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OBJECTIVES: The onset of LGS during early childhood brings particular concerns
for the child with LGS and for the parents caring for the child with the condition.
LGS is a severe form of childhood epilepsy which is characterized by multiple seizures
and mental deﬁ ciency. This study was conducted to explore the impact of LGS on the 
HRQL of the parent and the child and to develop a conceptual model. METHODS:
Semi-structured interviews were conducted with 40 parents of children with LGS
in the US, UK, and Italy. Given the fact that it was not possible to interview the
children, parents were asked to provide a report on their perceptions of the HRQL 
of their child in addition to describing the impact on their own HRQL. Thematic
analysis using Atlas TI was conducted to develop themes relating to the impact 
on HRQL. The themes were organized into a conceptual model of the impact of LGS
on the HRQL of the parent and the child. RESULTS: Parents reported extensive dif-
ﬁ culties in every aspect of their own lives. Major themes included burden of care on 
work and social activities, stigma, frustration, anxiety and other physical issues
(including sleep disturbance), as well as concerns about the future for their child. With 
respect to the HRQL of the child, the parents reported that the physical functioning 
of the child is affected, particularly in relation to mobility difﬁ culties. LGS has a sig-
niﬁ cant affect on a child’s cognitive skills with some of the children not being able to 
talk. In addition, children with LGS tend to have little or no social skills and ﬁ nd
interacting with others difﬁ cult. CONCLUSIONS: LGS has a substantial negative 
effect on the HRQL of parents of a child with LGS as well as on the HRQL of the 
child him/herself.
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UTILITIES FOR MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A
SURVEY OF THE GENERAL PUBLIC IN CANADA
Tarride JE, Oremus M, Clayton N, Raina P
McMaster University, Hamilton, ON, Canada
OBJECTIVES: (1) To elicit health utility scores for moderate Alzheimer’s disease (AD)
using the Canadian general public; (2) to compare utility scores for Canadians’ 
self-assessed health status with utility scores for health status deﬁ ned as moderate AD;
(3) to measure awareness of AD; and (4) to determine factors that inﬂ uence utility
scores. METHODS: Five-hundred Canadians were chosen randomly to participate in 
a 13-minute telephone interview. The sample was national in scope and stratiﬁ ed by 
income. The EQ-5D was administered to measure utility for respondents’ current
health status (i.e., no AD). After describing moderate AD, respondents were asked to 
answer the EQ-5D again, this time imagining they had moderate AD. AD awareness
was measured with the Alzheimer’s Disease Knowledge Test (ADKT). Respondents
were also asked about socio-demographics and whether they knew someone with AD. 
OLS regressions were conducted to identify determinants of EQ-5D utility scores. 
RESULTS: The mean age of respondents was 51 years, 61% were female, and 42% 
knew someone with AD (e.g., family member). Mean ADKT score was 3.4 (SD: 1.1) 
out of 5 (higher scores indicate better knowledge of AD). Respondents’ mean EQ-5D 
score for their current health status was 0.857 (SD: 0.15). Mean EQ-5D score for a
hypothetical, moderate AD health status was 0.638 (SD: .20), a utility decrement of 
0.22. For the VAS component of the EQ-5D, scores were higher for the current health 
status (79.16 versus 57.66). Age and income were signiﬁ cant explanatory variables 
for current health status utilities, but only age was signiﬁ cant in the determination of 
the utility score under the assumption of moderate AD. Gender, knowledge of someone
with AD, or AD awareness scores had no impact. CONCLUSIONS: When measured 
by the EQ-5D, Canadians would expect to assign a lower utility to their health status 
when they have moderate AD.
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THE IMPACT OF DIFFERENT STAGES OF MULTIPLE SCLEROSIS ON
HEALTH UTILITIES: A SYSTEMATIC REVIEW OF THE LITERATURE
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OBJECTIVES: Multiple Sclerosis (MS) causes neurological disability of varying 
severity. Disability in MS is measured by the Kurtzke Expanded Disability Status
Scale (EDSS), a clinician-based neurological impairment rating scale (scale from 1 to 
